美国 · SEC FORM 4
HARROW, INC.
HROW · Nasdaq · CIK 0001360214 · Healthcare · Drug Manufacturers—Specialty & Generic
内部人信号
4 位买方 · 4 条买入交易行 · $468.7K 买入总额
为什么有这个信号？
评分构成
每条进度条表示其对当前分数的贡献；权重和公式保持不变。
哪些因素限制了当前分数？
- ⚠ Purchase size is modest relative to the model scale
- ⚠ 角色得分低 · 买入者中职位最高的是：CHIEF EXECUTIVE OFFICER（CEO、董事长和持股 10% 以上的股东得分最低）
- ⚠ Purchase activity is becoming less recent
- ⚠ Buying conviction is reduced by concurrent selling
- ✓ Cluster breadth is broad · 4+ insiders
Purchase-size comments are relative to the model scale. Average daily volume is a separate market-context diagnostic.
US-v1.2 按当前 180 天规则给合资格的股票买入打分。分数只表示研究的先后，不是收益预测或概率。回测没有显示美国分数越高、之后的表现越好。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型；卖出仅作为背景。
—
买方广度与集中度
Roles in the peak window: CHIEF EXECUTIVE OFFICER, Director, PRESIDENT AND CFO. Concentration uses priced qualifying P lines only and does not change the saved score.
信号历史
最新留档分数
- 45.0
- 44.9
- 44.9
- 44.9
- 44.8
Only scores saved when a full US scoring run completed are shown; gaps are not reconstructed.
近期 Form 4 活动
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
市场背景补充近期价格表现与风险信息，不影响内部人信号。
价格表现
- 1M
- -19.7%
- 3M
- -29.8%
- 6M
- -18.3%
- 12M
- -26.1%
波动率与流动性
- 波动率
- 62.7%
- Beta
- —
- 平均每日成交额
- USD 16.9M
估值
- 市值
- USD 1.1B
- P/E
- —
基本面
- 利润率
- -1.9%
- ROE
- -9.8%
- 细分行业
- Drug Manufacturers—Specialty & Generic
市场数据
价格数据截至：2026-10-11 · 价格来源：OpenBB/yfinance; 成交量来自 本机价格缓存 (yfinance) · 来自 SEC 申报文件：市值, 利润率, ROE · 财年截止日：2025-12-31 · 市值 = 申报文件封面所列的已发行股数 × 最新收盘价。股数日期：2026-08-06 · Status: PASS
空头余额
空头余额是券商向 FINRA 申报的外部背景数据，不影响内部人信号。
- 空头股数
- 7,762,798
- 上期报告
- 7,488,381
- 日均成交量
- 626,927
- 回补天数
- 12.4
FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-05-18 | SILVERNAIL LAUREN P | 买入 (P) | Common Stock | 1,000 | USD 31.00 | USD 31,000 | SEC 申报 ↗ |
| 2026-05-18 | Graves Adrienne L | 买入 (P) | Common Stock | 1,000 | USD 31.07 | USD 31,070 | SEC 申报 ↗ |
| 2026-05-14 | BOLL ANDREW R. | 买入 (P) | Common Stock | 3,500 | USD 29.90 | USD 104,650 | SEC 申报 ↗ |
| 2026-05-14 | BAUM MARK L | 买入 (P) | Common Stock | 10,000 | USD 30.20 | USD 302,000 | SEC 申报 ↗ |
| 2024-04-25 | Opaleye Management Inc. | 买入 (P) | Common Stock, par value $0.001 per share | 20,000 | USD 9.97 | USD 199,400 | SEC 申报 ↗ |
| 2024-04-24 | Opaleye Management Inc. | 买入 (P) | Common Stock, par value $0.001 per share | 8,285 | USD 10.15 | USD 84,093 | SEC 申报 ↗ |
| 2024-04-23 | Opaleye Management Inc. | 买入 (P) | Common Stock, par value $0.001 per share | 11,715 | USD 10.29 | USD 120,547 | SEC 申报 ↗ |
| 2024-04-19 | Opaleye Management Inc. | 买入 (P) | Common Stock, par value $0.001 per share | 29,400 | USD 10.56 | USD 310,464 | SEC 申报 ↗ |
| 2024-03-28 | Opaleye Management Inc. | 买入 (P) | Common Stock, par value $0.001 per share | 50,000 | USD 12.82 | USD 641,000 | SEC 申报 ↗ |
| 2024-03-22 | BAUM MARK L | 买入 (P) | Common stock | 9,000 | USD 11.59 | USD 104,310 | SEC 申报 ↗ |
| 2024-03-20 | Opaleye Management Inc. | 买入 (P) | Common Stock, par value $0.001 per share | 50,600 | USD 9.65 | USD 488,290 | SEC 申报 ↗ |
| 2023-11-16 | BAUM MARK L | 买入 (P) | Common Stock | 7,500 | USD 8.11 | USD 60,825 | SEC 申报 ↗ |
| 2023-11-15 | Opaleye Management Inc. | 买入 (P) | Common Stock, par value $0.001 per share | 25,000 | USD 8.03 | USD 200,750 | SEC 申报 ↗ |
| 2023-09-20 | Opaleye Management Inc. | 买入 (P) | Common Stock, par value $0.001 per share | 5,983 | USD 14.49 | USD 86,694 | SEC 申报 ↗ |
| 2023-09-19 | Opaleye Management Inc. | 买入 (P) | Common Stock, par value $0.001 per share | 14,017 | USD 14.65 | USD 205,349 | SEC 申报 ↗ |
Form 4 申报证据
16 transaction lines in the latest 365-day window; 150 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-08-14 | Shojaei Amir | 卖出 (S) | Common Stock | 11,250 | USD 40.00 | USD 450,000 | SEC 申报 ↗ |
| 2026-08-14 | Shojaei Amir | 期权行权／转换 (M) | Common Stock | 11,250 | USD 35.96 | USD 404,550 | SEC 申报 ↗ |
| 2026-05-18 | SILVERNAIL LAUREN P | 买入 (P) | Common Stock | 1,000 | USD 31.00 | USD 31,000 | SEC 申报 ↗ |
展开近期 Form 4 证据 (14 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-08-14 | Shojaei Amir | 卖出 (S) | Common Stock | 11,250 | USD 40.00 | USD 450,000 | SEC 申报 ↗ |
| 2026-08-14 | Shojaei Amir | 期权行权／转换 (M) | Common Stock | 11,250 | USD 35.96 | USD 404,550 | SEC 申报 ↗ |
| 2026-05-18 | SILVERNAIL LAUREN P | 买入 (P) | Common Stock | 1,000 | USD 31.00 | USD 31,000 | SEC 申报 ↗ |
| 2026-05-18 | Graves Adrienne L | 买入 (P) | Common Stock | 1,000 | USD 31.07 | USD 31,070 | SEC 申报 ↗ |
| 2026-05-14 | BOLL ANDREW R. | 买入 (P) | Common Stock | 3,500 | USD 29.90 | USD 104,650 | SEC 申报 ↗ |
| 2026-05-14 | BAUM MARK L | 买入 (P) | Common Stock | 10,000 | USD 30.20 | USD 302,000 | SEC 申报 ↗ |
| 2026-03-04 | Opaleye Management Inc. | 卖出 (S) | Common Stock, par value $0.001 per share | 138,263 | USD 39.67 | USD 5,484,893 | SEC 申报 ↗ |
| 2026-03-03 | Opaleye Management Inc. | 卖出 (S) | Common Stock, par value $0.001 per share | 60,309 | USD 39.15 | USD 2,361,097 | SEC 申报 ↗ |
| 2026-02-27 | Opaleye Management Inc. | 卖出 (S) | Common Stock, par value $0.001 per share | 5,000 | USD 54.18 | USD 270,900 | SEC 申报 ↗ |
| 2026-01-06 | Opaleye Management Inc. | 卖出 (S) | Common Stock, par value $0.001 per share | 20,000 | USD 53.35 | USD 1,067,000 | SEC 申报 ↗ |
| 2025-12-12 | BOLL ANDREW R. | 期权行权／转换 (M) | Common Stock | 60,000 | USD 3.95 | USD 237,000 | SEC 申报 ↗ |
| 2025-12-12 | BOLL ANDREW R. | 代扣税 (F) | Common Stock | 26,665 | USD 47.06 | USD 1,254,855 | SEC 申报 ↗ |
| 2025-12-12 | BAUM MARK L | 期权行权／转换 (M) | Common Stock | 180,000 | USD 3.95 | USD 711,000 | SEC 申报 ↗ |
| 2025-12-12 | BAUM MARK L | 代扣税 (F) | Common Stock | 79,994 | USD 47.06 | USD 3,764,518 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-18 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | HROW |
| CIK | 0001360214 |
| 行业 | Healthcare |
| 细分行业 | Drug Manufacturers—Specialty & Generic Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 150 transaction lines from 2020-03-16 to 2026-08-14 71 P purchase lines · 24 S sale lines · 55 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.